BCHE and Parkinson disease: Nevertheless, ethopropazine (a BChE inhibitor approved by the FDA for treatment of Parkinson’s disease) is highly selective for BChE over AChE, with IC50 = 210–300 nM for BChE and IC50 = 210 μM for AChE (~1000-fold selectivity)24.